 |
Clinical Trial Questions?
|
 |
|
Randomized Study of a Cancer Information Service Research Consortium Multimedia
Educational Program in Patients With Early-Stage Prostate or Breast Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Related Information Registry Information
Alternate Title
Multimedia Educational Program for Patients With Early-Stage Prostate Cancer or Breast Cancer
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| No phase specified | Educational/Counseling/Training | Active | Not specified | AMCCRC-08-0498 08-0498, NCT00830635 |
Special Category:
NCI Web site featured trial Objectives Primary - Determine whether an innovative multimedia educational program will help newly
diagnosed prostate (project 1) and breast (project 2) cancer patients prepare for their
journey as cancer patients, promote informed treatment decision-making and reduce
cancer-specific distress, and among breast cancer patients at re-entry, facilitate an
informed re-entry transition to cancer survivorship and reduce cancer-specific distress
(project 3).
- Determine whether having Cancer Information Service (CIS) Information Specialists
make a scheduled telephone callback to callers in project 3 will augment and support use
of the CIS Research Consortium (CISRC) multimedia educational programs and further
enhance the study outcomes examined in this program of research.
- Determine whether the hypothesized mediational variables account for significant
intervention effects in each of the three component projects.
- Examine potential moderator variables to assess potential differences in intervention
efficacy by selected subgroups (e.g., age, education) within each component project.
- Conduct an in-depth tracking study of utilization patterns for a detailed description of
different patterns of use, as well as elucidating those components or modules within the
program that had differential utilization by participants.
- Assist the CIS and other similar cancer information systems in disseminating one or
more of the CISRC interventions should they prove effective in this program of research.
Secondary - Conduct secondary analyses across projects (i.e., perceived need for and benefit from
the CISRC interventions and intervention efficacy across three high priority cancer
patient populations) that will be made possible by the use of a common theoretical
framework, the same or similar intervention and research design across projects, and a
common set of endpoints.
Entry Criteria Disease Characteristics:
- Patients are diagnosed with 1 of the following:
- Diagnosis of prostate cancer (project 1)
- Early-stage disease
- Previously untreated disease or treatment status unknown
-
Diagnosis of breast cancer (projects 2-3)
- Early-stage disease
- No ductal carcinoma in situ or lobular carcinoma in situ
- Inflammatory breast cancer allowed (project 2)
- Previously untreated disease, receiving concurrent treatment, previously treated
disease, or treatment status unknown
- No more than 30 days since completion of treatment OR no more than 6 months post-treatment (project 3)
Prior/Concurrent Therapy:
- See Disease Characteristics
Patient Characteristics:
- Has access to a computer
- Willing to provide mailing address and telephone number
- Must be active information-seekers who have already called the CIS
- Understands English
Expected Enrollment 1800Outcomes Primary Outcome(s)Cancer-specific distress Emotional quality of life Physical functioning Interpersonal functioning Benefit-finding Decisional conflict (projects 1 and 2) Regret (projects 1 and 2) Fear of recurrence (project 3) Practical concerns (project 3)
Outline This is a multicenter study. Patients are assessed by demographic questions and a
baseline interview conducted by
Cancer Information Service (CIS) Information Specialists. Patients are randomized to 1
of 3
intervention groups: - Group 1: Patients receive a mailing containing standard CIS print materials. In project 1,
patients receive “
Treatment Choices for Men with Early-Stage Prostate Cancer” and
“What You Need to Know About Prostate Cancer”. In project 2, patients receive “What
You Need to Know About Breast Cancer” and “Surgery Choices for Women with Early-Stage Breast Cancer”. In project 3, patients receive “Facing Forward: Life After Cancer
Treatment” and “What You Need to Know About Breast Cancer”.
- Group 2: Patients receive mailings appropriate to their project as in group 1. Patients
also receive the multimedia program via the Internet or CD-ROM.
- Group 3: In project 3 only, patients receive mailings appropriate to their project as in
group 1 and the multimedia program as in group 2. Patients also receive a CIS callback
intervention at 10-14 days from trained Information Specialists from the CIS.
After completion of study therapy, patients are followed at 2 and 9 months.
Trial Contact Information
Trial Lead Organizations AMC Cancer Research Center  |  |  | | Alfred Marcus, PhD, Principal investigator |  | |  | Trial Sites
 |
 |
 |
 |
| U.S.A. |
 |
| Florida |
 |
| |
Miami |
 |
| | | | | | | | | University of Miami Sylvester Comprehensive Cancer Center - Miami |
| | | CIS Contact Center | |
|
| New York |
 |
| |
New York |
 |
| | | | Memorial Sloan-Kettering Cancer Center |
| | | CIS Contact Center | |
|
| Washington |
 |
| |
Seattle |
 |
| | | | Fred Hutchinson Cancer Research Center |
| | | CIS Contact Center | |
|
Related Information Featured trial article
| Registry Information |  | | Official Title | | Cancer Information Service Research Consortium: Years 2006-2011 Program Narrative and Overview |  | | Trial Start Date | | 2008-09-01 |  | | Trial Completion Date | | 2009-12-31 (estimated) |  | | Registered in ClinicalTrials.gov | | NCT00830635 |  | | Date Submitted to PDQ | | 2008-10-17 |  | | Information Last Verified | | 2009-02-16 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
 |